The Wellcome Trust has awarded $3.84 million to Karuna Pharmaceuticals Inc to further develop a novel treatment for schizophrenia that combines the experimental compound xanomeline with an approved medicine called trospium chloride. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
